Intellectual Property India Publishes Patent Application for 'Somatostatin Subtype-2 Receptor (SST2R) Targeted Therapeutics And Uses Thereof' Filed by Crinetics Pharmaceuticals, Inc.

MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517066416 A) filed by Crinetics Pharmaceuticals, Inc., San Diego, on July 11, for 'somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof.'

Inventor(s) include Zhao, Jian; Zhu, Yunfei; and Chen, Mi.

The application for the patent was published on July 25, under issue no. 30/2025.

According to the abstract released by the Intellectual Property India: "Described herein are somatostatin subtype-2 receptor (SST2R) targeted thereapeutics that target tumor cells expressing SST2R and their use in the treatment of cancer."

The patent application was internationally filed on Dec. 11, 2023, under International application No.PCT/US2023/083429.

Disclaimer: Curated by HT Syndication.